MedTrace Logo

Safety of Autologous M2 Macrophage in Treatment of Non-Acute Stroke Patients

NCT01845350 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2016-11-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether M2 macrophages are safe and feasible in the treatment of non-acute stroke patients

Conditions

Interventions

OTHER

M2 macrophage introduction

* Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients * Intrathecal introduction of autologous M2 macrophages

Sponsors & Collaborators

  • Siberian Branch of the Russian Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Elena R. Chernykh, MD, PhD · Research Institute of Clinical Immunology, Russian Academy of Medical Sciences (Siberian Branch)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-04-30
Completion
2015-10-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01845350 on ClinicalTrials.gov